Daniel Engelman to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Daniel Engelman has written about Randomized Controlled Trials as Topic.
Connection Strength
0.665
-
Ostermann M, Corteville DC, Doi K, Koyner JL, Lamy A, Li G, Solinsky CM, Winterberg PD, Smith WT, Mehta RL, Murray PT, Shaw AD, Zarbock A, Engelman DT. A phase 3 study of ravulizumab to protect patients with chronic kidney disease from cardiac surgery-associated acute kidney injury and major adverse kidney events (ARTEMIS). Trials. 2025 May 30; 26(1):181.
Score: 0.181
-
Spadaccio C, Salsano A, Pisani A, Nenna A, Nappi F, Osho A, D'Alessandro D, Sundt TM, Crestanello J, Engelman D, Rose D. Enhanced recovery protocols after surgery: A systematic review and meta-analysis of randomized trials in cardiac surgery. World J Surg. 2024 Apr; 48(4):779-790.
Score: 0.166
-
Beaton A, Okello E, Engelman D, Grobler A, Scheel A, DeWyer A, Sarnacki R, Omara IO, Rwebembera J, Sable C, Steer A. Determining the impact of Benzathine penicillin G prophylaxis in children with latent rheumatic heart disease (GOAL trial): Study protocol for a randomized controlled trial. Am Heart J. 2019 09; 215:95-105.
Score: 0.119
-
Hoogma DF, Meeusen I, Coppens S, Verbrugghe P, van den Eynde J, Engelman DT, Grant MC, Stoppe C, Rex S. Efficacy of enhanced recovery programmes for cardiac surgery: a systematic review and meta-analysis. Br J Anaesth. 2025 Jul; 135(1):31-39.
Score: 0.045
-
Rwebembera J, Ndagire E, Carvalho N, Webel AR, Sable C, Okello E, Sarnacki R, Spaziani AM, Mucunguzi A, Engelman D, Grobler A, Steer A, Beaton A. Intramuscular versus enteral penicillin prophylaxis to prevent progression of rheumatic heart disease: Study protocol for a noninferiority randomized trial (the GOALIE trial). Am Heart J. 2024 Sep; 275:74-85.
Score: 0.042
-
Nascimento BR, Nunes MCP, da Silva JLP, Steer A, Engelman D, Okello E, Rwebembera J, Zuhlke L, Mirabel M, Nakitto M, Sarnacki R, Ribeiro ALP, Sable CA, Beaton AZ. Outcomes of latent rheumatic heart disease: External validation of a simplified score in patients with and without secondary prophylaxis. Int J Cardiol. 2024 Mar 15; 399:131662.
Score: 0.041
-
Mazer CD, Siadati-Fini N, Boehm J, Wirth F, Myjavec A, Brown CD, Koyner JL, Boening A, Engelman DT, Larsson TE, Renfurm R, de Varennes B, Noiseux N, Thielmann M, Lamy A, Laflamme M, von Groote T, Ronco C, Zarbock A. Study protocol of a phase 2, randomised, placebo-controlled, double-blind, adaptive, parallel group clinical study to evaluate the efficacy and safety of recombinant alpha-1-microglobulin in subjects at high risk for acute kidney injury following open-chest cardiac surgery (AKITA trial). BMJ Open. 2023 04 06; 13(4):e068363.
Score: 0.039
-
Lake SJ, Phelan SL, Engelman D, Sokana O, Nasi T, Boara D, Gorae C, Schuster T, Grobler AC, Osti MH, Andrews R, Marks M, Whitfeld MJ, Romani L, Kaldor J, Steer A. Protocol for a cluster-randomised non-inferiority trial of one versus two doses of ivermectin for the control of scabies using a mass drug administration strategy (the RISE study). BMJ Open. 2020 08 30; 10(8):e037305.
Score: 0.033